Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCRECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

Videos | Structural Heart | September 16, 2020
Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) explains structural heart innovations and...
The Epiq CVxi being used for TEE imaging in the cath lab. The system brings together advanced image quality, quantification and intelligence specifically for the cardiologist.

The Epiq CVxi being used for TEE imaging in the cath lab. The system brings together advanced image quality, quantification and intelligence specifically for the cardiologist.

News | Cardiovascular Ultrasound | September 15, 2020
September 15, 2020 — Philips Healthcare recently introduced the latest addition to its portfolio of dedicated...
Videos | Pharmaceuticals | September 10, 2020
Matthew Budoff, M.D., director of cardiovascular CT at The Lundquist Institute, and professor of medicine at the David...
Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial
News | Pharmaceuticals | September 10, 2020
September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation...
Videos | Drug-Eluting Balloons | September 09, 2020
Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) worked on preclinical development work for a...
Biotronik's closed loop stimulation (CLS) technology helps reduce unexplained fainting in patients with recurrent episodes due to skipped heartbeats. #ESC2020
News | EP Lab | September 08, 2020
September 8, 2020 - A new study presented at the 2020 European Society of Cardiology (ESC) Congress shows that...
The BRACE CORONA trial presented at ESC Congress 2020 is the First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients.
News | Coronavirus (COVID-19) | September 08, 2020
September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin-...
Videos | TCT | August 01, 2020
With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular...
Echocardiography strain imaging at ASE. #ASE2020
News | ASE | August 20, 2020
August 20, 2020 – More than 350 posters featuring cutting edge research on the advances in cardiovascular ultrasound...
The World Alliance of Societies of Echocardiography (WASE) Normal Values Study is a cross-sectional study designed to obtain universal global reference ranges for both 2-D and 3-D echocardiographic (2DE, 3DE) data to identify geographical differences in echocardiographic measurements. Launched in 2016, the WASE study prospectively enrolled healthy individuals free from cardiac, lung, and kidney disease from 19 centers in 15 countries. #ASE #ASE2020
News | Cardiovascular Ultrasound | August 20, 2020
August 20, 2020 – The World Alliance of Societies of Echocardiography (WASE) Normal Values Study is a cross-sectional...
In the era of COVID-19, remote technical assistance has become big deal. GE Healthcare showed its Digital Expert technology at the ASE 2020 virtual meeting, which allows remote one-on-one echo training or ultrasound machine technical assistance. It became an important service for GE since the start of the pandemic. 

In the era of COVID-19, remote technical assistance has become big deal. GE Healthcare showed its Digital Expert technology at the ASE 2020 virtual meeting, which allows remote one-on-one echo training or ultrasound machine technical assistance. It became an important service for GE since the start of the pandemic. 

Feature | ASE | August 19, 2020
August 19, 2020 — From point-of-care ultrasound (POCUS) that has been a key technology during the COVID-19 pandemic, to...
aption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

Caption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

News | Artificial Intelligence | August 19, 2020
August 19, 2020 — Caption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA...
In February 2020, the U.S. Food and Drug Administration (FDA) cleared artificial intelligence software to assist in the acquisition of cardiac ultrasound images. The Caption Guidance software from Caption Health is an accessory to compatible diagnostic ultrasound systems and uses artificial intelligence to help the user capture images of a patient’s heart that are of acceptable diagnostic quality. It is aimed at point of care ultrasound (POCUS) exams, where users may not be regular sonographers.

In February 2020, the U.S. Food and Drug Administration (FDA) cleared artificial intelligence software to assist in the acquisition of cardiac ultrasound images. The Caption Guidance software from Caption Health is an accessory to compatible diagnostic ultrasound systems and uses artificial intelligence to help the user capture images of a patient’s heart that are of acceptable diagnostic quality. It is aimed at point of care ultrasound (POCUS) exams, where users may not be regular sonographers.

Feature | Artificial Intelligence | August 18, 2020 | Dave Fornell, Editor
The No. 1 overarching hot topic at all the medical conferences over the past couple years has been artificial...
COVID-19 has a big impact on the heart, and patients with pre-existing cardiovascular disease have at least a 10 percent higher risk of death and severe complications due to the virus. The virus also can cause myocarditis, blood clotting, and impact the cardiovascular system due to severe, hyperactive inflammatory responses.  Left, a cardiac CT scan 3-D rendering. right, the COVID-19 virus from a National Institutes of Health (NIH) photo.

COVID-19 has a big impact on the heart, and patients with pre-existing cardiovascular disease have at least a 10 percent higher risk of death and severe complications due to the virus. The virus also can cause myocarditis, blood clotting, and impact the cardiovascular system due to severe, hyperactive inflammatory responses.  Left, a cardiac CT scan 3-D rendering. right, the COVID-19 virus from a National Institutes of Health (NIH) photo.

Feature | Coronavirus (COVID-19) | August 17, 2020
August 17, 2020 - The number of people coronavirus disease 2019 (COVID-19) is rising with more cases in the U.S. There...
Sheer stresses on the walls of arteries are believed to cause the formation atherosclerotic plaques. This is an area of research that is expected to see increased use in the next few years. This study was presented at SCCT 2020 as an example of how sheer stresses can help evaluate and predict the patency of coronary artery bypass grafts (CABG). #SCCT2020 #yesCCT

Sheer stresses on the walls of arteries are believed to cause the formation atherosclerotic plaques. This is an area of research that is expected to see increased use in the next few years. This study was presented at SCCT 2020 as an example of how sheer stresses can help evaluate and predict the patency of coronary artery bypass grafts (CABG).

Feature | CT Angiography (CTA) | August 14, 2020 | Dave Fornell, Editor
The latest technical advances and trends in computed tomography (CT) and the latest clinical study data were discussed...